Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

about

Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer

P2860

Q39438832-10028581-2A63-4B53-8900-67E35E5709BE Q57788662-518CC2B7-661F-4DD9-AC01-D12EAA7B5110

P2860

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

Item

http://www.wikidata.org/entity/Q38796209

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Is regorafenib providing clini ...... metastatic colorectal cancer?

@en

type

Item

label

Is regorafenib providing clini ...... metastatic colorectal cancer?

@en

prefLabel

Is regorafenib providing clini ...... metastatic colorectal cancer?

@en

P1476

Is regorafenib providing clini ...... metastatic colorectal cancer?

@en

P2093

C Grávalos

http://www.w3.org/2001/XMLSchema#string

J Feliú

http://www.w3.org/2001/XMLSchema#string

J García-Foncillas

http://www.w3.org/2001/XMLSchema#string

J Sastre

http://www.w3.org/2001/XMLSchema#string

P García-Alfonso

http://www.w3.org/2001/XMLSchema#string

P2860

Cetuximab for the treatment of colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

SHP-1 is a target of regorafenib in colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.

P2888

s12094-016-1499-8

P304

1072-1081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-016-1499-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rocío García-Carbonero

CARMEN GUILLEN PONCE

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27037815

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

about

P2860

P2860

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921